EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 38 / No 8-9 (Août-Septembre 2022) Med Sci (Paris), 38 8-9 (2022) 707-713 References
Open Access
Issue
Med Sci (Paris)
Volume 38, Number 8-9, Août-Septembre 2022
Page(s) 707 - 713
Section Repères
DOI https://doi.org/10.1051/medsci/2022109
Published online 12 September 2022
  1. ONUSIDA. https://www.unaids.org/fr. [Google Scholar]
  2. Barré-Sinoussi F. L’infection VIH/sida : l’histoire exemplaire d’une épidémie qui résiste. Med Sci (Paris) 2018 ; 34 : 499–500. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Vernazza P, Hirschel B, Bernasconi Eet al. Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisses 2008 ; 89 : 165–169. [CrossRef] [Google Scholar]
  4. Cohen MS, Chen YQ, McCauley Met al. Prevention of HIV-1 Infection with Early Antiretroviral Therapy. N Engl J Med 2011 ; 365 : 493–505. [CrossRef] [PubMed] [Google Scholar]
  5. Supervie V. Les moyens de prévention de l’infection à VIH à base d’antirétroviraux - Quel impact sur l’épidémie du VIH ?. Med Sci (Paris) 2013 ; 29 : 373–382. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. EurekaSanté par V. Les complications de l’infection par le VIH/sida. EurekaSanté. [Google Scholar]
  7. Pialoux G, Raffi F, Brun-Vezinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 1998 ; 339 : 1269–1276. [CrossRef] [PubMed] [Google Scholar]
  8. Marchou B, Tangre P, Charreau I, et al. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 2007 ; 21 : 457–466. [PubMed] [Google Scholar]
  9. Paterson DL, Swindells S, Mohr J, et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection. Ann Intern Med 2000 ; 133 : 21–30. [CrossRef] [PubMed] [Google Scholar]
  10. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group. AIDS 1999 ; 13 : 677–683. [Google Scholar]
  11. García F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999 ; 13 : F79–F86. [CrossRef] [PubMed] [Google Scholar]
  12. Dybul M, Chun TW, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001 ; 98 : 15161–15166. [CrossRef] [PubMed] [Google Scholar]
  13. Dybul M, Nies-Kraske E, Dewar R, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 2004 ; 189 : 1974–1982. [CrossRef] [PubMed] [Google Scholar]
  14. Reynolds SJ, Kityo C, Hallahan CW, et al. A Randomized, Controlled, Trial of Short Cycle Intermittent Compared to Continuous Antiretroviral Therapy for the Treatment of HIV Infection in Uganda. PLOS ONE 2010 ; 5 : e10307. [CrossRef] [PubMed] [Google Scholar]
  15. Cohen CJ, Colson AE, Sheble-Hall AG, et al. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials 2007 ; 8 : 19–23. [CrossRef] [PubMed] [Google Scholar]
  16. The BREATHER (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. Lancet HIV 2016; 3 : e421–30. [CrossRef] [PubMed] [Google Scholar]
  17. Leibowitch J, Mathez D, de Truchis P, et al. Short cycles of antiretroviral drugs provide intermittent yet effective therapy: a pilot study in 48 patients with chronic HIV infection. FASEB J 2010 ; 24 : 1649–1655. [CrossRef] [PubMed] [Google Scholar]
  18. Article R4127–8 - Code de la santé publique - Légifrance. [Google Scholar]
  19. Zehnacker L, Abe E, Mathez D, et al. Plasma and Intracellular Antiretroviral Concentrations in HIV-Infected Patients under Short Cycles of Antiretroviral Therapy. AIDS Res Treat 2014 ; 2014 : 724958. [PubMed] [Google Scholar]
  20. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997 ; 277 : 112–116. [CrossRef] [PubMed] [Google Scholar]
  21. de Truchis P, Assoumou L, Landman R, et al. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162–4D trial. J Antimicrob Chemother 2018 ; 73 : 738–747. [CrossRef] [PubMed] [Google Scholar]
  22. Guardo AC, Zarama A, González T, et al. Effects on immune system and viral reservoir of a short-cycle antiretroviral therapy in virologically suppressed HIV-positive patients. AIDS 2019 ; 33 : 965–972. [CrossRef] [PubMed] [Google Scholar]
  23. Landman R, Truchis P de, Assoumou L, et al. A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial. Lancet HIV 2022; 9 : e79–90. [CrossRef] [PubMed] [Google Scholar]
  24. Amiel P, Chneiweiss H, Dosquet C. Covid-19 : protocoles de soins ou protocoles de recherche ? Med Sci (Paris) 2020; 36 : 521–3. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  25. Leibowitch J, Mathez D, de Truchis P, et al. Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project. FASEB J 2015 ; 29 : 2223–2234. [CrossRef] [PubMed] [Google Scholar]
  26. Barbot J. Les interactions entre les associations et les agences publiques dans l’organisation de la recherche d’un traitement contre le sida. Revue française des affaires sociales 2001 ; 59–63. [CrossRef] [Google Scholar]
  27. Persiaux R. ARV : Leibowitch pilote l’allègement ! Seronet 2011. [Google Scholar]
  28. Persiaux R. Iccarre : côtés ailes, ca colle, côté sous, ça coule ! Le meilleur du VIH en 2011 : retour sur un an de stratégies. Seronet 2012. [Google Scholar]
  29. Persiaux R. Projet Iccarre d’allègement du traitement VIH : la polémique en débat. Seronet 2012. [Google Scholar]
  30. Calin R, Landowski S, Valantin M-A, et al. Efficacy of intermittent short cycles of integrase inhibitor-based maintenance ART in virologically suppressed HIV patients. J Antimicrob Chemoth 2020; 75 : 1321–23. [CrossRef] [PubMed] [Google Scholar]
  31. Luise D, Lattuada E, Rizzardo S, et al. Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy. J Antimicrob Chemoth 2022; 77 : 747–52. [CrossRef] [PubMed] [Google Scholar]
  32. ANRS, Emerging Infectious Diseases. Randomized, Open-label and Multicentric Trial Evaluating the Non-inferiority of Antiretroviral Dual Therapy Taken 4 Consecutive Days Per Week Versus Antiretroviral Dual Therapy 7/7 Days Per Week in HIV-1 Infected Patients With Controlled Viral Load Under Antiretroviral Dual Therapy. clinicaltrials.gov, 2021. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.